Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

Mutations in the MET exon 14 RNA splice acceptor and donor sites, which lead to exon skipping, deletion of the juxtamembrane domain containing the Cbl E3-ubiquitin ligase binding site, and decreased turnover of the resultant aberrant MET protein, were previously reported to be oncogenic in preclinic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Paik, Paul K., Drilon, Alexander, Fan, Pang-Dian, Yu, Helena, Rekhtman, Natasha, Ginsberg, Michelle S., Borsu, Laetitia, Schultz, Nikolaus, Berger, Michael F., Rudin, Charles M., Ladanyi, Marc
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4658654/
https://ncbi.nlm.nih.gov/pubmed/25971939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-1467
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados